Lotte Biologics signs antibody drug CMO deal with UK’s Ottimo Pharma
BOSTON – Lotte Biologics Co. has signed a deal to manufacture an antibody therapy for British biotech startup Ottimo Pharma as the South Korea...
S.Korea’s Lunit installs breast cancer AI diagnostic tool at 200 US hospitals
Lunit Inc., a South Korean AI-powered cancer diagnostics company, said on Monday that more than 200 healthcare institutions across the US have now a...
CJ CheilJedang scraps $3.5 bn green bio sale, shifts gears to expansion
CJ CheilJedang Corp., South Korea’s largest food and beverage company, said on Wednesday it has scrapped a planned sale of its green bio busin...
Celltrion unveils cancer medicine to expand new drug pipelines
South Korea’s leading biosimilar drug developer Celltrion Inc. on Sunday unveiled an anticancer medicine to expand new pipelines and accelerat...
ABL Bio lands $2.8 billion license-out deal with GSK
ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-bas...
SillaJen: First to use lab-grown human tissue to find best cancer drug dose
South Korean biotechnology firm SillaJen Inc. is pioneering a new approach to determine the best dose for a cancer drug combination in clinical tria...
MBK Partners poised to acquire CJ Cheiljedang’s $3.5 billion bio business
North Asia-focused private equity firm MBK Partners is on the verge of clinching a major acquisition deal by offering a higher bid than other conten...
MBK Partners, 2 Chinese firms vie for CJ Cheiljedang’s $4 bn bio business
North Asia-focused private equity firm MBK Partners and two leading Chinese biotechnology firms are vying for management control of CJ Cheiljedang C...
Celltrion’s Vegzelma: Most-prescribed cancer treatment in Europe
South Korea’s leading biosimilar drug developer Celltrion Inc.'s Vegzelma, a cancer drug referencing global biopharma Roche’s Avastin, h...
Samsung Biologics signs initial deal with LigaChem Bio on ADC production
Samsung Biologics Co., the world’s largest contract drugmaker, said on Thursday it has signed an initial agreement with LigaChem Biosciences I...
Yuhan’s lung cancer drug gets OK in Europe
Leclaza (ingredient: lazertinib), a new lung cancer treatment developed by South Korea’s Yuhan Corp. secured approval from the European Commis...
HD Hyundai Oilbank supplies bio VLSFO to Yangming
HD Hyundai Oilbank Co., a South Korean crude oil refiner backed by Saudi Aramco, said on Thursday it started to supply Taiwan-based Yang Ming Marine...
Blackstone, Carlyle, MBK vying for CJ CheilJedang’s bio business
Blackstone, Carlyle Group and MBK Partners have joined the race to purchase the bio business of CJ CheilJedang Corp., the world’s largest prod...
Latvian President Rinkēvičs seeks closer ties with S.Korea in bio, defense
Latvian President Edgars Rinkēvičs, who is on a four-day working trip to South Korea, said on Friday he hopes for deeper cooperation between the two...
President of Latvia visits S.Korea's Daan Cancer Lab
Daan Cancer Laboratory under Severance Hospital said on Thursday it signed a memorandum of understanding (MOU) with the Latvian government to streng...
CJ CheilJedang puts bio business on market for $4 bn
CJ CheilJedang Corp., South Korea’s largest food company, is seeking to sell its bio business for about 6 trillion won ($4.3 billion) in what ...
Korea’s Lunit in AI-powered lung cancer diagnostics deal with AstraZeneca
Lunit Inc., a South Korean AI-powered cancer diagnostics company, has partnered with global biopharma giant AstraZeneca plc. to jointly enter the AI...
Volpara to supply breast cancer SW to US Defense Health Agency
Lunit, a South Korean cancer diagnostics AI company, said on Monday its US subsidiary Volpara Health secured a 10 billion won ($7.5 million) contr...
LG Chem targets functional cosmetics market with bio-materials
LG Chem Ltd., the world’s fourth-largest chemicals manufacturer, is targeting the functional cosmetics market with bio-materials derived from ...
Celltrion's anti cancer drugs hold 90% market share in C.America
South Korea’s Celltrion Inc. said on Friday that its cancer treatments have captured a 90% market share in several Central American countries....
Celltrion to supply breast, stomach cancer treatment to Brazil
Celltrion Inc., South Korea’s largest biosimilar maker, announced on Friday that its breast and stomach cancer treatment "Herzuma" (active ing...
After 37 years of use, Kim returns trusty microwave to Samsung with love
For 37 years, a simple microwave made by Samsung Electronics Co. sat in the kitchen of Kim Kyu-won, providing much more than convenience.It was ther...
Lotte to restructure bio business to focus on CDMO
South Korea’s retail-to-chemical conglomerate Lotte Group will restructure its bio business to focus on the profit-making medicine bio develop...
SK Group’s 3rd-generation daughter comes to the fore
Chey Yoon-chung, the eldest daughter of SK Group Chairman Chey Tae-won, unexpectedly made her debut during an SK Biopharmaceuticals Co. video confer...
Gencurix, Hitachi to cooperate on molecular diagnostics
South Korean biotech company Gencurix Inc. said on Tuesday that it will cooperate with Japan's Hitachi High-Tech Corporation to enter the Japanese c...
Hyundai Motor releases 2025 Santa Fe
Hyundai Motor Co. said on Tuesday that it released the 2025 Santa Fe, a model year change of its flagship midsize sports utility vehicle (SUV) The A...
Volpara to supply cancer diagnostics SW to Intermountain Health
Lunit, a South Korean cancer diagnostics AI company, announced on Wednesday that its subsidiary Volpara Health, a New Zealand-based AI software deve...
Yuhan’s lung cancer drug clears FDA hurdle for global debut
A new lung cancer treatment developed by South Korea’s Yuhan Corp. has secured approval from the US Food and Drug Administration (FDA) as a co...
Korea's investment forum KIW 2024 kicks off September 9
South Korea’s largest investment forum Korea Investment Week 2024 (KIW 2024) will kick off next month in Seoul, drawing around 150 leaders fro...
Biotech stocks, foreigners’ top pick in Korea amid panic selling
Foreigners and institutional investors in the South Korean stock market picked biotechs as their favorite shares in hopes of a biopharma stock jump ...
